证券代码：001300 证券简称：三柏硕 公告编号：2025-021 青岛三柏硕健康科技股份有限公司 关于部分募集资金投资项目重新论证并延期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 青岛三柏硕健康科技股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日分别召开第二届董事会第八次会议、第二届监事会第八次会议，审议通过《关 于部分募集资金投资项目重新论证并延期的议案》，本事项无需提交公司股东大 会审议。现将有关情况公告如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于核准青岛三柏硕健康科技股份有限公司首 次公开发行股票的批复》（证监许可[2022]2054 号）核准，青岛三柏硕健康科技 股份有限公司向社会公开发行人民币普通股（A 股）60,943,979 股，每股面值 1 元，每股发行价格 11.17 元，募集资金总额人民币 680,744,245.43 元，扣除各项 发行费用合计人民币 70,090,350.29 元，实际募集资金净额为 610,653,895.14 元。 截至 2022 年 10 月 14 日止，实际募集资 ...

青岛三柏硕健康科技股份有限公司 2024 年度财务决算及 2025 年预算报告 第一部分 2024 年度财务决算报告 一、本年度主要会计数据和财务指标 | | 2024 年 | 2023 年 | 本年比上年 | 2022 年 | | --- | --- | --- | --- | --- | | | | | 增减 | | | 营业收入（元） | 551,843,636.01 | 332,147,746.38 | 66.14% | 567,133,246.47 | | 归属于上市公司股东 | 22,269,198.00 | -42,937,284.83 | 151.86% | 65,701,589.28 | | 的净利润（元） | | | | | | 归属于上市公司股东 的扣除非经常性损益 | 11,537,274.30 | -52,900,628.30 | 121.81% | 62,265,646.84 | | 的净利润（元） | | | | | | 经营活动产生的现金 流量净额（元） | 21,056,572.48 | 4,625,850.42 | 355.19% | 58,079,091.39 | | 基 ...

证券代码：001300 证券简称：三柏硕 公告编号：2025-025 青岛三柏硕健康科技股份有限公司 关于使用部分暂时闲置募集资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 青岛三柏硕健康科技股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日分别召开了第二届董事会第八次会议、第二届监事会第八次会议，审议通 过了《关于使用部分暂时闲置募集资金进行现金管理的议案》，同意在确保不 影响募集资金投资计划正常进行和募集资金安全的情况下，公司使用最高不超 过人民币 5 亿元的暂时闲置募集资金进行现金管理，使用期限自董事会审议通 过之日起 12 个月内，单个投资产品的投资期限不超过 12 个月。额度范围内资 金可循环滚动使用。现将具体事项公告如下： 一、募集资金基本情况 经中国证券监督管理委员会（以下简称"中国证监会"）《关于核准青岛 三柏硕健康科技股份有限公司首次公开发行股票的批复》（证监许可〔2022〕 2054号）核准，并经深圳证券交易所同意，公司向社会公开发行人民币普通股 6,094.3979万股，每股发行价格为11.17元， ...

证券代码：001300 证券简称：三柏硕 公告编号：2025-027 青岛三柏硕健康科技股份有限公司 关于召开 2024 年年度股东大会的通知 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在任何虚假记载、误导 性陈述或者重大遗漏。 2、网络投票时间：2025 年 5 月 20 日。其中，通过深圳证券交易所交易系统进行网络 投票的具体时间为：2025 年 5 月 20 日上午 9:15-9:25、9:30-11:30，下午 13:00-15:00；通过 深圳证券交易所互联网投票系统投票的具体时间为：2025 年 5 月 20 日上午 9:15-下午 15:00 期间任意时间。 （五）召开方式：本次股东大会采用现场投票与网络投票相结合的方式。 1、现场投票：现场出席及通过填写授权委托书授权他人出席。 2、网络投票：公司将通过深圳证券交易所交易系统和互联网投票系统 （ http://wltp.cninfo.com.cn）向公司股东提供网络形式的投票平台，公司股东可以在上 述网络投票时间内通过上述系统行使表决权。公司股东只能选择现场投票和网络投票中 的一种表决方式，表决结果以第一次有效投票结果为准。 （六 ...

一、 审议通过《2024 年年度报告及其摘要》 经审查，监事会认为：董事会编制、审议《2024 年年度报告》和《2024 年 年度报告摘要》的程序符合法律、行政法规及中国证监会的规定，报告内容真实、 准确、完整地反映了上市公司的实际情况，不存在任何虚假记载、误导性陈述或 者重大遗漏。 表决情况：3 票同意，0 票反对，0 票弃权。 上述议案尚需提交 2024 年年度股东大会审议。 二、审议通过《2024 年度监事会工作报告》 具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn）的《2024 年度监事会工作报告》。 表决情况：3 票同意，0 票反对，0 票弃权。 证券代码：001300 证券简称：三柏硕 公告编号：2025-014 青岛三柏硕健康科技股份有限公司 第二届监事会第八次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确和完整，不存在任何虚假 记载、误导性陈述或者重大遗漏。 青岛三柏硕健康科技股份有限公司（以下简称"公司"）第二届监事会第八 次会议于 2025 年 4 月 25 日以现场和通讯方式召开，会议通知于 2025 年 4 月 15 日以专人送达、通讯、邮件等形式 ...

证券代码：001300 证券简称：三柏硕 公告编号：2025-013 青岛三柏硕健康科技股份有限公司 第二届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 青岛三柏硕健康科技股份有限公司（以下简称"公司"）第二届董事会第八 次会议于 2025 年 4 月 25 日以现场和通讯方式召开，会议通知于 2025 年 4 月 15 日以专人送达、通讯、邮件等形式送达。会议应出席董事 7 名，实际出席董事 7 名。公司董事长朱希龙先生主持本次会议。会议的召集、召开符合《中华人民共 和国公司法》等法律法规及《青岛三柏硕健康科技股份有限公司章程》的规定。 公司监事、高级管理人员列席本次会议。 与会董事对本次会议的全部议案进行了充分讨论，审慎表决，形成如下决议： 一、审议通过：《2024 年年度报告及其摘要》 表决情况：7票同意，0票反对，0票弃权。 具体内容详见公司同日刊登在《证券时报》《证券日报》《中国证券报》《上 海证券报》《经济参考报》和巨潮资讯网（www.cninfo.com.cn）的《2024 年年度 报告》《2024 年年度报告摘要》（ ...

证券代码：001300 证券简称：三柏硕 公告编号：2025-015 青岛三柏硕健康科技股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、 审议程序 青岛三柏硕健康科技股份有限公司（以下简称"公司"）于2025年4月25日 分别召开了第二届董事会第八次会议及第二届监事会第八次会议，审议通过《关 于2024年度利润分配预案的议案》，该议案尚需提交公司2024年年度股东大会审 议。 二、2024年度利润分配预案基本情况 经和信会计师事务所（特殊普通合伙）审计，公司2024年度实现归属于上市 公司股东的净利润22,269,198.00元，母公司实现净利润37,597,214.25元，根据《公 司法》和《公司章程》规定，提取法定盈余公积3,759,721.43元。截至2024年12月 31日，公司合并报表可分配利润为167,443,170.10元，母公司可分配利润为 177,398,895.33元。根据利润分配应以母公司的可供分配利润及合并财务报表的 可供分配利润孰低的原则，截至2024年12月31日公司可供股东 ...

Financial Performance - The company's revenue for Q1 2025 was ¥138,409,098, a decrease of 12.34% compared to ¥157,895,723 in the same period last year[5] - Net profit attributable to shareholders was ¥6,526,018, down 46.61% from ¥12,223,697 in the previous year[5] - The net profit after deducting non-recurring gains and losses was ¥4,087,618, reflecting a decline of 56.61% from ¥9,421,464 in the same period last year[5] - Total operating revenue decreased to ¥138,409,098 from ¥157,895,723.53, a decline of approximately 12.3% year-over-year[18] - Net profit for the period was ¥6,527,432.22, down from ¥12,223,697.03, representing a decrease of approximately 46.5% year-over-year[19] - Earnings per share (basic and diluted) decreased to ¥0.0268 from ¥0.0501, a decline of about 46.5%[19] Cash Flow and Investments - The net cash flow from operating activities improved by 48.13%, reaching -¥15,872,432 compared to -¥30,598,207 in the previous year[5] - Cash inflow from investment activities totaled $756.54 million, significantly up from $382.62 million in the previous period[22] - Cash outflow from investment activities was $782.61 million, compared to $518.62 million last year, resulting in a net cash flow from investments of -$26.07 million[22] - Financing activities generated a net cash inflow of $9.06 million, reversing from a net outflow of -$0.92 million in the previous period[23] - The company's cash and cash equivalents decreased by $32.63 million, ending the period with a balance of $219.30 million[23] - Cash inflow from sales of goods and services was $133.49 million, up from $84.90 million year-over-year[22] - Cash received from tax refunds increased to $9.41 million, compared to $8.74 million in the previous period[22] - Total cash outflow for operating activities was $160.93 million, compared to $126.06 million last year[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,271,133,243.89, a decrease of 3.42% from ¥1,316,149,336.10 at the end of the previous year[5] - Current assets total 1,024,620,517.71 RMB, a decrease from 1,062,964,735.76 RMB in the previous period[16] - Total liabilities decreased to ¥217,541,209.74 from ¥260,536,279.33, a reduction of approximately 16.5%[17] - Total equity attributable to shareholders decreased to ¥1,050,590,620.10 from ¥1,055,613,056.77, a slight decline of about 0.5%[17] Shareholder Information - Total number of common shareholders at the end of the reporting period is 20,651[11] - The largest shareholder, Qingdao Haishuo Health Industry Development Co., Ltd., holds 47.30% of shares, totaling 115,317,531 shares[11] - The company has a total of 19.52% shares held by J.LU INVESTMENTS LLC, amounting to 47,583,346 shares[11] - The company has repurchased a total of 1,295,000 shares, accounting for 0.53% of the total share capital, with a total transaction amount of 15,780,745.00 RMB[13] Operational Highlights - The company reported a significant increase in short-term borrowings, rising by 178.62% to ¥27,609,277.77 from ¥9,909,277.77[8] - The company experienced a 63.56% increase in taxes and additional charges, totaling ¥1,360,419.31 compared to ¥831,769.57 in the previous year[8] - The company has not reported any new product developments or market expansion strategies in this quarter[5] - The company reported a financial expense of -¥1,499,434.36, compared to -¥1,445,861.31 in the previous period, indicating a slight increase in financial costs[18] - Other comprehensive income after tax decreased to -¥110,037.11 from ¥729,213.02, indicating a significant decline in this area[19]

Financial Performance - The company's operating revenue for 2024 reached ¥551,843,636.01, representing a 66.14% increase compared to ¥332,147,746.38 in 2023[6]. - The net profit attributable to shareholders for 2024 was ¥22,269,198.00, a significant turnaround from a loss of ¥42,937,284.83 in 2023, marking a 151.86% improvement[6]. - The cash flow from operating activities increased by 355.19% to ¥21,056,572.48 in 2024, compared to ¥4,625,850.42 in 2023[6]. - Basic earnings per share for 2024 were ¥0.0914, up 151.90% from a loss of ¥0.1761 in 2023[6]. - Total assets at the end of 2024 were ¥1,316,149,336.10, reflecting a 9.75% increase from ¥1,199,263,425.05 at the end of 2023[6]. - The company reported a significant increase in net profit after deducting non-recurring gains and losses, reaching ¥11,537,274.30 in 2024, compared to a loss of ¥52,900,628.30 in 2023, a 121.81% improvement[6]. - The company's total revenue for 2024 reached ¥551,843,636.01, representing a 66.14% increase compared to ¥332,147,746.38 in 2023[61]. - The trampoline segment generated ¥183,848,615.10, accounting for 33.32% of total revenue, with a year-on-year growth of 40.03%[61]. - Fitness equipment sales surged by 108.52%, totaling ¥188,258,985.11, which represents 34.11% of total revenue[61]. - The North American market contributed ¥188,069,086.06, a 49.35% increase from ¥125,923,078.71 in the previous year[61]. Dividend and Shareholder Information - The company plans to distribute a cash dividend of 0.10 RMB per 10 shares to all shareholders, based on a total of 242,480,914 shares[6]. - The company reported a cash dividend of ¥0.10 per 10 shares (including tax), totaling a cash dividend distribution of ¥2,424,809.14, which represents 100% of the total profit distribution[157][159]. - The distributable profit for the reporting period was ¥167,443,170.10[157]. Business Operations and Strategy - The company is positioned in the sports goods manufacturing industry, focusing on leisure sports and fitness equipment[32]. - The company focuses on the research, design, production, and sales of leisure sports and fitness equipment, with a product portfolio of approximately 31 series and over 1,000 products[45]. - The company has established stable partnerships with international retailers and sports brands, including Decathlon, Walmart, and Amazon, enhancing its market presence[52]. - The company is committed to continuous technological innovation and product development, aiming to strengthen its position as a leader in the trampoline sector[45]. - The company is currently developing a new easy-install basketball hoop to enhance product competitiveness and brand influence in the market[72]. - A new foldable trampoline is under development, aimed at capturing market demand and enhancing product competitiveness for long-term growth[72]. - The company is working on a home fitness series that combines multiple functions and is designed for easy storage, targeting the growing home fitness market[72]. - Development of a smart running machine suitable for home use is ongoing, which aims to meet diverse fitness needs and strengthen the company's technological leadership in the fitness equipment industry[72]. - The company is also focusing on developing a waterproof and durable table tennis table to enhance user experience and extend product lifespan[72]. - A modular training combination device is being developed to cater to various training needs, which is expected to enrich the product range and enhance market competitiveness[72]. Market Trends and Industry Insights - Recent government policies aim to enhance the fitness equipment industry, promoting public sports services and expanding facility supply[33]. - The fitness equipment industry in China had a business climate index of 152.9, indicating a strong market performance driven by sustained household fitness demand and the recovery of commercial gym markets[38][39]. - The trampoline industry in China is experiencing growth due to policy support and increased health awareness, with trampolines becoming popular for home fitness and family entertainment[41]. - The global trampoline market is expected to recover in 2024 as consumer spending on non-essential items increases, following a period of economic fluctuation[40]. - The integration of smart devices and online courses is accelerating the trend of home workouts, creating new opportunities for the fitness industry[42]. - The industry is shifting towards smart and professional products, with consumers increasingly valuing intelligent interaction and personalized fitness solutions[43]. - The children's and elderly fitness markets are expanding simultaneously, driven by rising health awareness and the aging population, creating a dual growth engine[44]. - Cross-border e-commerce is opening global sales channels for the sports goods industry, although challenges such as domestic competition and international barriers remain[44]. Research and Development - The company’s R&D capabilities are supported by a comprehensive technical system that covers the entire chain from research to market application, enabling rapid product development[53]. - Research and development (R&D) investment amounted to CNY 23.997 million in 2024, reflecting a 5.58% increase from CNY 22.728 million in 2023[74]. - The proportion of R&D investment to operating revenue decreased from 6.84% in 2023 to 4.35% in 2024 due to the significant revenue increase[75]. - The company expanded its R&D personnel to 93 in 2024, a 3.33% increase from 90 in 2023[74]. - The number of R&D personnel with a master's degree rose by 12.50% from 8 in 2023 to 9 in 2024[74]. Governance and Compliance - The company has established a governance structure that complies with relevant laws and regulations, ensuring independent operation from controlling shareholders[117]. - The company has a complete financial accounting system and does not share bank accounts with controlling shareholders, ensuring financial independence[121]. - The company has a comprehensive business system and operates independently from its controlling shareholders, with no significant related party transactions[123]. - The company maintains a high level of transparency and compliance in its governance practices, with no significant discrepancies from regulatory requirements[117]. - The company has established a complete organizational structure and internal management system to support its independent operations[122]. - The company has successfully conducted multiple shareholder meetings, with resolutions passed in accordance with legal procedures[125]. Employee and Talent Management - The total number of employees at the end of the reporting period is 1,031, with 443 in the parent company and 588 in major subsidiaries[151]. - The professional composition includes 680 production personnel, 66 sales personnel, and 62 technical personnel[151]. - The company provides various employee benefits, including meal allowances, free shuttle buses, and team-building activities, in addition to mandatory social insurance[153]. - The company has established a performance execution mechanism based on its operational philosophy and strategic goals, ensuring competitive salary levels through annual salary surveys[153]. Financial Management and Investment - The company has implemented a fundraising management system to ensure effective control over the use of raised funds, with no violations reported during the reporting period[174]. - The financial department is responsible for the financial management of investment projects, ensuring compliance with relevant regulations[172]. - The company has established an investment management system to regulate investment activities, covering production, non-production, equity investments, and others[171]. - The company has committed to a production project for trampoline manufacturing, with an expected completion date in 2024 and an investment of 6.37 million[92]. - A new research and development center project is underway, with an investment of 8.20 million and a projected completion date in 2026[92]. Risk Management - The company faces risks from international trade policy changes, high reliance on overseas markets, and increasing competition, and is implementing strategies to mitigate these risks[108][110][111]. - The company is monitoring foreign exchange fluctuations closely to manage risks associated with its predominantly overseas sales[112]. Environmental and Social Responsibility - The company has obtained various environmental permits, including a wastewater discharge permit valid until July 18, 2028[199]. - The company has implemented measures to reduce carbon emissions, ensuring compliance with environmental standards[199]. - The company emphasizes the protection of creditor rights and adheres to relevant laws and agreements in credit cooperation[200]. - The company has established a commitment to providing fair working conditions and career development opportunities for employees[200].

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 青岛三柏硕健康科技股份有限公司（以下简称"公司"）于2024年4月26日 分别召开第二届董事会第三次会议及第二届监事会第三次会议，审议通过《关于 使用部分闲置募集资金暂时补充流动资金的议案》，同意公司及子公司在确保不 影响募投项目正常实施的前提下，结合实际经营需求和财务状况，使用不超过人 民币1.5亿元的闲置募集资金暂时补充流动资金，使用期限自公司董事会审议通 过之日起不超过12个月，到期归还至募集资金专户。在上述额度及期限内，资金 可循环滚动使用。具体内容详见公司刊登在《证券时报》《证券日报》《中国证 券报》《上海证券报》《经济参考报》和巨潮资讯网（www.cninfo.com.cn）的《关 于使用部分闲置募集资金暂时补充流动资金的公告》（公告编号：2024-019）。 截至本公告日，公司未使用闲置募集资金暂时补充流动资金。公司已将上述 情况通知了公司保荐机构及保荐代表人。 特此公告。 证券代码：001300 证券简称：三柏硕 公告编号：2025-011 青岛三柏硕健康科技股份有限公司 关于提前归还暂时补充流动 ...